Research Services Agreement

This research services agreement (”Agreement”) is made on the Effective Date (see below) by and between:

DECRETO DEL DIRETTORE GENERALE - N. 4655 del 18/11/2026 - Allegato Utente 1 (A01)

(1) **Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico,** VAT no. 04724150968, the administrative seat of which is located at Milano, Via Francesco Sforza 28-20122, represented by Chief Scientific Officer, Prof. Fabio Blandini, granted of the powers to sign this deed (Council Resolution of the Institution n. 10 of 03/27/2024)
(hereinafter referred to as “*Institution*”);

and

(2) TARGED BIOPHARMACEUTICALS B.V., a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) incorporated under the laws of the Netherlands with its registered address at Princetonlaan 6, 3584 CB, Utrecht, the Netherlands and registered at the Trade register of the Chamber of Commerce under number 78502969; and
(hereinafter referred to as “*TargED*”)

which are also each referred to hereinafter as a “*Party*” and which are also both collectively referred to hereinafter as the “*Parties*”;

WHEREAS:

(a) Institution, through the research group of Prof. Flora Peyvandi, has certain expertise and know-how in the area of Thrombotic Microangiopathies;

(b) TargED is a biopharmaceutical company that develops first-in-class biological drugs to improve treatment of thrombosis.

(c) As part of its research and development efforts, TargED is engaged in the clinical development of TGD001 (a therapeutic protein comprising the catalytic domain of urokinase fused to a single-domain antibody (VHH) that anchors the protein to blood clots) as a therapy targeted clot breakdown (thrombolysis) at the site of thrombosis.

(d) TargED is the Sponsor of a clinical trial entitled: “An Adaptive Dose Escalation and Expansion Basket Trial to Explore the Safety, Pharmacology, and Clinical Activity of TGD001 in Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP) and Other Thrombotic Microangiopathies" (hereinafter the “Trial” or the “Study”), concerning version no. 3.0 of the Protocol Code TG1-CL-301 dated 13/Feb/2026 and any amendments duly approved (hereinafter the “Protocol”), EU CT number 2025523802-34-00; In the framework of the Trial, TargED

wishes for Institution to carry out, on behalf of TargED, certain research services, which research services will be mutually agreed between the Parties and which will be specified in the schedules to this Agreement;

(e) Institution agrees to carry out, on behalf of TargED and subject to the further terms and conditions as outlined herein, said research services;

(f) TargED agrees to provide to Institution, and Institution agrees to receive from TargED, certain materials and information of a proprietary and/or confidential nature, solely for use by Institution in said research services and subject to the further terms and conditions outlined herein,

(g) Institution and TargED wish to make further arrangements on the performance of the research services by Institution, on the use of said materials and said information by Institution, as well as on the rights to the results and deliverables from said research services, which arrangements are as outlined herein;

(h) Institution has the necessary expertise and know-how at the Department of Neuroradiology;

NOW THEREFORE, in consideration of the mutual covenants and promises hereinafter set forth, it is mutually agreed by and between the Parties as follows:

Article 1: Definitions.

1.1. "*Institution Technology*" shall mean any and all methods, procedures, techniques and equipment for the assessment of brain images and the measurement of VWF multimer levels in plasma samples from participants in the TG1-CL-301 trial.

1.2. "*Confidential Information*" shall have the meaning set forth in Article 5 of this Agreement.

1.3. "*Deliverables*" shall mean the Deliverables from the Services, which deliverables shall be mutually agreed between the Parties and which are as specified in the Schedule(s).

1.4. *Effective Date*" shall mean date of last signature.

1.5. "*Inventions*" shall mean any results, inventions, improvements, further developments and/or modifications, whether patentable or not, that are made, generated, conceived and/or reduced to practice by Institution in performing the Services and/or using the TargED Materials; it being understood and agreed that Inventions shall not include any improvements, further developments and/or modifications of the Institution Technology that do not make use of, contain and/or otherwise involve the TargED Materials.

1.6. "*Schedule*" shall mean a schedule to this Agreement, which shall be mutually agreed between the Parties, made in writing, and shall only become effective upon signing by both Parties.

1.7. "*Services*" shall mean the research services performed by Institution on behalf of TargED, which research services are as specified in the Schedule(s).

1.8. *"TargED Materials*" shall mean the materials provided by (or on behalf of) TargED to Institution pursuant to this Agreement (including but not limited to clinical samples generated by or on behalf of TargED as part of a clinical trial for which TargED is the sponsor).

1.9. Plural shall mean singular and visa versa.

Article 2: Services.

2.1. Subject to the further terms and conditions of this Agreement, Institution agrees to use reasonable commercial efforts (1) to perform the Services on behalf of TargED in accordance with the Schedule A; and (2) to provide TargED with the Deliverables in accordance with the Schedule A.

2.2. TargED agrees that the Institution Technology is and shall remain proprietary to Institution. Any improvements, further developments and/or modifications of the Institution Technology that do not make use of, contain and/or otherwise involve the TargED Materials shall be proprietary to Institution.

2.3. The Schedules and any amendments thereof shall be mutually agreed in writing between Institution and TargED, and shall at least contain:

a) a description of the Services and timelines;

b) a description of the TargED Materials to be provided by TargED to Institution;

c) the Deliverables to be provided by Institution to TargED;

d) the payment(s) to be made by TargED to Institution in accordance with Article 4 of this Agreement.

2.4. Institution agrees that the TargED Materials are and shall remain proprietary to, and are and shall remain the sole property of, TargED.

2.5. Institution agrees to use the TargED Materials solely for the purposes of the Services and thus agrees not to use the TargED Materials for any other purpose without prior written approval of TargED.

2.6. Institution agrees not disclose, to transfer or to otherwise make available (any of) the TargED Materials to any third party or entity without prior written approval of TargED.

2.7. Institution agrees not to reverse engineer, to analyse and/or to otherwise determine the (structure of) the TargED Materials, nor to attempt to do so, directly or indirectly through the use of a third party.

2.8. Institution agrees that it shall not perform the Services with any third party or entity without prior written approval of TargED.

2.9. Institution agrees that it shall perform the Services, and that it shall store, use and where applicable dispose of, the TargED Materials, solely within its own premises.

Article 3: Deliverables and Inventions.

3.1. Institution acknowledges and agrees that any and all Deliverables and Inventions shall be proprietary to TargED, and thus that all right, title and interest to any and all Deliverables and Inventions shall vest in TargED. Institution shall promptly disclose all Inventions to TargED. Article 5.4 shall apply.

3.2. TargED shall have the right, at TargED's sole discretion and expense, to apply for and to obtain intellectual property rights (including but not limited to patent applications and patents) to any and all Deliverables and Inventions. Institution shall assign to TargED, and shall ensure that its officers, employees and agents shall assign to TargED, any and all rights that Institution and its officers, employees and/or agents may have to Deliverables and Inventions. Institution shall further assist TargED, and shall ensure that its officers, employees and agents shall assist TargED, with the filing, obtainment of and maintenance of such intellectual property rights for Deliverables and Inventions by executing all papers and instruments and by making all rightful oaths and declarations as may be necessary for the drafting, filing, assignment, prosecution and maintenance thereof, such upon request by TargED. Institution agrees that it shall be solely responsible for the payment of any and all compensation that its officers, employees or agents are or may be entitled to under any applicable agreement or law as inventor of any Deliverables or Inventions and/or in consideration of the assignment of their rights to any Deliverables or Inventions to TargED. Institution warrants and represents that it shall pay such compensation promptly upon the date that the same may become due, and agrees to indemnify TargED, its shareholders, directors, employees, agents and assigns, and each and all of them, against, and to hold them harmless from, any action or claim made against them for any such compensation.

3.3. Other than for the purposes of performing the Services, nothing in this Agreement grants or shall be construed to grant to Institution any right or any license to the Deliverables, to any Inventions, to any intellectual property rights filed for or obtained by TargED pursuant to Article 3.2, or to any part of any of the foregoing; nor to grant to Institution any claim or option to any such right or license.

Article 4: Payments

4.1. In consideration of (1) the timely performance of the Services by Institution on behalf of TargED; (2) Institution providing the Deliverables and the final report to TargED; and (3) the further rights and licenses granted by Institution to TargED hereunder; TargED agrees to pay to Institution the amount(s) mentioned in the Schedule(s), which will be mutually agreed between the Parties.

4.2. Any payments pursuant to Article 4.1 shall be made in Euros within 40 (forty) working days from receipt by TargED of a written invoice, which invoice shall specify the Services to which said invoice relates, the amount(s) payable, and the bank account number to which payment should be made. Institution shall send such invoices in accordance with the Schedule(s).

All payments hereunder are expressed to be exclusive of goods, sales, value added or any similar such tax ("VAT") and TargED shall in addition to the payments hereunder pay VAT (at the applicable rate) where: (i) Institution is or will be liable to any competent authority for VAT in respect of such payment; and (ii) the Institution has invoiced the amount payable together with applicable VAT.

Article 5: Confidentiality.

5.1. The Parties acknowledge that for the purposes of this Agreement, it may be necessary for a Party to provide the other Party with, and/or for the Parties to exchange, certain information that is of a confidential and/or of a proprietary nature.

5.2. In accordance with Article 5.1, for the purposes of this Agreement, the term "*Confidential Information*" shall mean any and all information that is disclosed or otherwise made available by a Party (also referred to as the "*Disclosing Party*") to the other Party (also referred to as the "*Receiving Party*") during the term of this Agreement and/or that otherwise comes into the possession of the Receiving Party from the Disclosing Party during the term of this Agreement and that is either at the time of disclosure thereof to the Receiving Party marked "Confidential" and/or properly labeled and/or that is confirmed by the Disclosing Party to the Receiving Party in writing as being confidential no later than 30 days after the date of disclosure thereof to the Receiving Party.

Said information may be in any form, including but not limited to written form, graphic form, oral form, physical form and/or digital form; and may include, but is not limited to:

a) information on the Disclosing Party and/or on the Disclosing Party's business, including but not limited to financial data, commercial data, business and/or scientific proposals, and/or information on negotiations (including but not limited to any negotiations between the Parties);

b) scientific and/or technical knowledge, including but not limited to know-how, procedures, protocols, (clinical study) results, data, formulae, representations, algorithms, computer programs, technical drawings and/or designs, and/or information on modifications, further developments, improvements and/or inventions (whether patentable or not);

c) any information relating to the TargED Materials;

d) personal data and identity of the study subjects.

5.3. Notwithstanding Articles 5.1 and 5.2, it is understood and agreed that the term Confidential Information as used in this Agreement shall not include any information for which the Receiving Party can demonstrate, by means of its written records, that such information:

a) was already in the possession of the Receiving Party prior to the disclosure of said information to the Receiving Party by the Disclosing Party;

b) which is or later becomes public knowledge other than through breach of any provision of this Agreement by the Receiving Party and/or through the fault of the Receiving Party; and/or

c) was disclosed to the Receiving Party on a non-confidential basis by an independent third party, which independent third party was also not under any obligation of confidentiality to the Disclosing Party with respect to said information;

d) was independently developed by the Receiving Party without use of or reference to Confidential Information.

5.4. Notwithstanding Articles 5.1 and 5.2, it is understood and agreed that the Deliverables, any Inventions and any and all information and documents relating thereto shall constitute Confidential Information and that for the purposes of Articles 5.5 to 5.8 and of Article 9.1, TargED shall be deemed the Disclosing Party thereof and Institution shall be deemed the Receiving Party thereof.

5.5. Each Party acknowledges that any and all Confidential Information received under this Agreement from the other Party is and shall remain proprietary to the other Party.

5.6. Each Party agrees, for a period of at least 10 (ten) years from the Effective Date, to keep confidential and to utilize its reasonable commercial efforts (which at a minimum shall be no less than the efforts that said Party makes with respect to its own confidential information) to protect and preserve the confidential status of any and all of the Confidential Information received from the other Party. Consequently, each Party agrees, for a period of at least 10 (ten) years from the Effective Date, not to disclose or otherwise make available to any third party the Confidential Information received from the other Party, and/or any part(s) thereof, without prior written permission of said other Party.

5.7. Each Party agrees to use the Confidential Information received from the other Party solely for the purposes of this Agreement and thus agrees not to use the Confidential Information received from the other Party, or any part(s) thereof, for any other purpose without prior written approval of the other Party.

5.8. The obligations of confidentiality that arise out of this Agreement shall not apply to the extent that a Party shall be required, by order or regulation of a governmental agency or court of competent jurisdiction, and as evidenced by said Party's written records, to disclose the Confidential Information received from the other Party, or any part(s) thereof, to said governmental agency or court of competent jurisdiction, provided that that the Receiving Party will provide the Disclosing Party with prompt notice of such request(s) so that the Disclosing Party may seek an appropriate protective order and/or waive the Receiving Party's compliance with the provisions of this Agreement.

Article 6: Record keeping and Reporting

6.1. Institution agrees to maintain proper records (the "Records") in respect of its performance of the Services, including any Deliverables obtained and any Inventions conceived and/or reduced to practice or otherwise made as part of the Services. During the Term and thereafter during the Retention Period, Institution shall (1) retain the Records and keep them safe and confidential; (2) upon written request by TargED (which shall not be unreasonably made), make the Records available for inspection and review by TargED; and (3) upon written request by TargED which shall not be unreasonably made, and at the sole cost of TargED, provide copies of the Records or any part(s) thereof to TargED, as requested. The Retention Period shall start upon expiry of the Term and shall be (1) 15 (fifteen) years for any Records that relate to, and/or that are generated as part of and/or for the purposes of, any clinical trials involving human subjects; and (2) 3 (three) years for any other Records. Upon expiry of the Retention Period, before destroying or discarding any of the Records, Institution shall offer to transfer the Records to TargED at TargED's expense.

Article 7: Term and Termination.

7.1. This Agreement is deemed to have entered into force on the Effective Date and shall remain in full force and effect until each Party has met in full its obligations ("*Term*").

7.2. Notwithstanding Article 7.1, this Agreement may be terminated (1) at any time by mutual written agreement between the Parties; (2) by TargED at 30 (thirty) days written notice. Termination pursuant to this Article 7.2 shall not affect the rights and obligations (including but not limited to the right to receive or the obligation to make any payments) on the part of either Party which have accrued prior to the date of such termination.

7.3. Notwithstanding Article 7.1, if a Party defaults in the performance of, or fails to be in compliance with, any material provision, condition or covenant of this Agreement, and any such default or non-compliance shall not have been remedied, or steps initiated to remedy the same, to the reasonable satisfaction of the other Party within 60 (sixty) days after receipt by the defaulting Party of a pertinent written notice by said other Party, said other Party shall have the right, at its sole discretion, either (1) to defer, upon written notice to the defaulting Party, the performance of its obligations under this Agreement until such time that such default or non-compliance has been remedied; or (2) to forthwith terminate this Agreement in writing. Termination pursuant to this Article 7.2 shall not affect the obligations (including but not limited to any obligation to make any payments) on the part of the defaulting Party which have accrued prior to the date of such termination.

7.4. Upon termination of this Agreement, each Party shall, upon written request by the other Party, immediately return to the other Party or destroy (any and all copies of) all documents and all electronic files describing or containing Confidential Information, and if such documents and/or electronic files are destroyed, promptly provide the other Party with written confirmation

thereof; provided that said Party may retain one copy of the Confidential Information in its legal records solely to ensure its continuing compliance with its obligations hereunder.

7.5. Further to Article 7.4, upon termination of this Agreement, Institution shall:

a) immediately cease any and all use of the TargED Materials;

b) upon written request by TargED, immediately return to TargED and/or destroy any remaining supplies of TargED Materials, and if such remaining supplies are destroyed, promptly provide TargED with written confirmation thereof.

7.6. The following Articles shall survive termination of this Agreement for any reason: 2.2, 2.4 to 2.9, 3, 5, 6, 7, 8 and 9; as well as those rights and/or obligations that by their intent or meaning have validity beyond the termination of this Agreement.

Article 8: Representations and Warranties.

8.1. Each Party warrants and represents that it is entitled to enter into this Agreement and to meet any and all of the obligations that may arise on its part out of this Agreement.

8.2. Institution warrants and represents that it shall use its reasonable commercial efforts to carry out the Services and to provide TargED with the Deliverables in accordance with the Schedule(s). However, it is understood and agreed, and TargED accepts, that Institution makes no representations and also does not extend any warranties, either expressed or implied, as to the successful completion and/or the outcome of the services, nor to the deliverables, including but not limited to any warranties of merchantability or fitness for any particular purpose.

8.3. Institution further warrants and represents that:

a) it shall perform the Services and in accordance with: (a) all applicable European regulations pertaining to investigational drugs, and such current Good Clinical Practice requirements as may be applicable; (b) the OECD Principles on Good Laboratory Practice and all local Good Laboratory Practices principles, as applicable in the country in which the Services are performed; (c) all applicable supranational, national, state and local laws, regulations and requirements, including but not limited to environmental laws and regulations, the national data protection regulations, all legal requirements relating to the rights of the patient (including but not only those relating to patient privacy) and all legal requirements that are applicable to experiments on the human person; (d) the Declaration of Helsinki and (e) the principle of medical secret and the protection of patient privacy;

b) it shall code, store and protect information regarding the subjects, biological material obtained from the subject and any recorded data in accordance with the laws, regulations and requirements referred to in paragraph a of this Article 8.3, as well as in accordance with applicable data privacy laws such as the General Data Protection Regulation (GDPR) or equivalent laws that apply in the countries where the data is collected, stored and/or processed;

c) it shall handle, store and where applicable dispose of all TargED Materials with the highest degree of care with regard to toxicological and environmental dangers associated therewith and in accordance with the applicable laws, rules, regulations and directives of applicable authorities; and that proper procedures are in place and shall be observed in order to ensure such proper handling of the TargED Materials; and that all TargED Materials shall be made available only to officers, employees or agents of Institution adequately trained in such procedures;

d) in addition to paragraph c), where the TargED materials comprise samples or other patient-derived materials that have been obtained in the context of a clinical trial, to handle, code, store and process such samples in accordance with the rules and regulations referred to in paragraph a).

8.4. Each Party acknowledges and agrees that any and all materials that it may receive from the other Party pursuant to this Agreement (including but not limited to the TargED Materials and any materials included in the Deliverables):

a) are materials of an investigational medicinal nature.

b) are, as of the moment said Party takes receipt thereof, provided to it and subsequently used by it entirely at its own risk and without any liability to the other Party.

8.5. It is acknowledged and agreed that each Party shall perform its obligations and exercise its rights under this Agreement at its own risk and sole liability.

Each Party agrees to indemnify the other Party and its shareholders, directors, employees, agents and assigns (and each and all of them) against, and to hold the same harmless from, any action, claim or liability (including, without limitation, liability for death, personal injury, property damage or product liability) arising out of the performance by the firstmentioned Party of its obligations under this Agreement or arising out of the exercise by the firstmentioned Party of any of its rights under this Agreement. This Article 8.5 shall not apply in case of gross negligence, willful misconduct and/or breach of warranty by the other Party, in which case the other Party shall indemnify the firstmentioned Party and its shareholders, directors, employees, agents and assigns, and each and all of them, and shall hold the same harmless from, any action, claim or liability (including without limitation liability for death, personal injury, property damage or product liability) arising therefrom.

8.6. For the execution of the Activities, TargED, in its capacity of Data Controller, shall appoint Institution Data Processor in compliance with art. 28 GDPR. In processing the Activities, Institution shall:

- Adopt technical and organizational measures appropriate to ensure the clinical data are adequately protected with the purpose to ensure the security of the processing.
- Ensure the confidentiality, the integrity, the availability and the resilience of the

systems and services used for the processing;

- Ensure the ability to restore availability and access to the clinical data in a timely manner in the event of a physical or technical accident;
- Maintain a procedure to test, verify and evaluate regularly the effectiveness of the technical and organizational measures to ensure the security of the processing;
- Only share the clinical data with personnel, who has undertaken to keep the confidentiality of the personal data or has an adequate legal confidentiality obligation and that has been previously trained on personal data protection legislation;
- Prevent the access of unauthorized individuals to the personal data processing systems (physical control of the access);
- Prevent the unauthorized use of the personal data processing systems (logical control of the access);
- Ensure that the individuals entitled to use the personal data processing systems will have access only to personal data of their competence, in compliance with their access rights, and that, during processing or use and after the storage, personal data cannot be read, copied, modified or deleted without authorization (control of data access);
- Ensure that personal data cannot be read, copied, modified or deleted without authorization during electronic transmission, transport or storage on storage devices and the addresses entities of any transfer of personal data through data transmission equipment can be identified and verified (control of data transfer, including encryption);
- Ensure the creation of a control procedure to report whether and by whom personal data have been inserted, modified or removed by personal data processing systems (audit);
- Ensure that personal data are processed exclusively according to the instruction of the data controller (instructions' control);
- Ensure that personal data are protected against the accidental destruction or loss and ensure the back up and the continuity (availability control).
- Provide the clinical data to third parties or interested subjects only after prior written consent of the Sponsor.

If the Institution becomes aware of a personal data breach, shall immediately inform the Sponsor, also reporting the circumstances of the violation and providing to the Sponsor any relating documentation. After consulting with Sponsor, the Institution must immediately adopt the necessary measures to secure the data and to minimize any eventual adverse consequence for the data subjects, informing, if necessary, the competent supervisory authority.

The Sponsor as the Controller undertakes to:

- Provide the Processor with the documented instructions for the processing data;
- Document, in writing, any instruction bearing on the processing of data by the Processor
- Ensure, before and throughout the processing, compliance with the obligations set out in the General Data Protection Regulation on the processor's part;
- Supervise the processing, including by conducting audits and inspections with the processor.
- Obtain, for each clinical data, the expressed consent of the patients to the processing of personal data for scientific research purpose. The patients shall be adequately informed, especially of their right to withdrawal the consent to the processing of their personal data. The Controller undertakes to keep the Institution indemnified and harmless from any legal actions or claims of the patient related to their rights of personal data or inventions, results and trade secrets generated during the Study.
- Hold indemnified and harmless the Processor from any legal actions, claims, questions or actions from the Data Subject or from a third party, including the Authority, related to an unauthorized use of Personal Data.

Article 9: Miscellaneous.

9.1. Other than expressly provided for in this Agreement, nothing in this Agreement grants or shall be construed to grant to any Party any right and/or any license to any intellectual property right or to any application for any intellectual property rights (including but not limited to patent applications or patents) that are held by and/or that are in the name of the other Party, nor to any Confidential Information that said Party has received from the other Party. Also, nothing in this Agreement grants or shall be construed to grant any claim or option to any right or license referred to in this Article 9.1.

9.2. Unless expressly provided otherwise herein, nothing in this Agreement gives either Party the right to use the name of the other Party in any manner without prior written consent of said other Party. However, TargED shall have the right, at its sole discretion, to use the name of Institution in any and all communications with (potential) clients, partners, licensees, collaborators, consultants and/or investors.

9.3. Both Parties are independent contractors under this Agreement. Consequently, nothing in this Agreement is intended or may be construed so as to establish a partnership or joint venture between the Parties and neither Party shall have the authority (actual or apparent) to bind the other Party. Also, unless expressly provided otherwise herein, each Party shall bear its own expenses incurred in performing its obligations under this Agreement.

9.4. This Agreement (including any and all of its Schedules) represents the entire understanding between the Parties with respect to the subject matter hereof. This Agreement shall also not bind

any of the Parties to reach or conclude any further agreements, and nothing in this Agreement is intended or may be construed as granting any option to negotiate or to conclude any further agreements. Any amendments to this Agreement and/or to its Schedules shall be made in writing and shall only become effective upon signing by both Parties.

9.5. Unless expressly provided otherwise herein, this Agreement supersedes any and all prior negotiations, representations, agreements and understandings between the Parties with respect to the subject matter contained in this Agreement.

9.6. This Agreement shall also be binding upon the legal successors of the Parties. Also, neither Party shall be allowed to assign or transfer any of its rights and/or any of its obligations arising out of this Agreement, either in full or in part, to any third party without prior written permission of the other Party, at said other Party's sole discretion; provided that each Party may, at its sole discretion but upon prior written notification to the other Party, assign the benefit of this Agreement to its legal successor in connection with a merger or similar reorganization of, or in connection with the sale of all or substantially all of the assets or stocks in, the business to which this Agreement relates, whereupon this Agreement shall also be inure to the benefit of and be binding upon such legal successor.

9.7 The provisions of this Agreement are severable, and in the event that any provision of this Agreement shall be determined to be invalid or unenforceable under any controlling body of the law, such invalidity or unenforceablility shall not in any way affect the validity or enforceability of the remaining provisions hereof. It is further the intention of the Parties that in lieu of each such provision which is invalid, illegal, or unenforceable, there be substituted or added as part of this Agreement, a provision which shall be as similar as possible in economic and business objectives as intended by the Parties to such invalid, illegal, or unenforceable provision, but which shall be valid, legal, and enforceable, and shall be mutually agreed by the Parties.

9.8. This Agreement may be executed in several counterparts, each of which shall be deemed to be original and each of which shall constitute one and the same Agreement. This Agreement may be executed by means of written execution copies or by exchange of copies of this Agreement by facsimile, by electronic image scan transmission in .pdf format or by a mutually agreed/used system for e-signature (such as DocuSign).

9.9. The headings in this Agreement are for convenience only and will not be deemed to affect in any way the language of the provisions to which they refer, nor in any way determine or influence the interpretation thereof. The Parties agree that in the event of any dispute concerning the interpretation or construction of this Agreement or any of its provisions, no presumption shall exist with respect to the Party that initially drafted this Agreement or first proposed said provision. The Parties each agree they have had ample opportunity to influence the choice of language and terms used in this Agreement.

9.10. Neither Party shall be responsible or liable for any delay, default or failure of it to perform its obligations under this Agreement by reason of any matter or occurrence outside its reasonable control (including, without limitation, fire, floods, earthquakes, natural disasters, embargoes, war, acts of war (whether war be declared or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, acts of God or acts, laws, regulations or other governmental restrictions, or acts, omissions and/or delays in acting by any governmental authority, provided that such Party, as soon as practicable, gives written notice to the other Party specifying the matters giving rise to such delay, default or failure, together with such evidence as it can reasonably give and specifying the period for which it is estimated such default, delay or failure will continue, and promptly resumes performance of its obligations as soon as it is reasonably able to do so.

9.11. Failure of any Party to assert and/or enforce any of its rights under this Agreement will neither be construed nor act as a waiver by said Party to later assert and/or enforce said right relative to the particular situation involved.

9.12. Any notice required by and/or sent under this Agreement shall be in writing and shall be sent by pre-paid, first class, certified mail, addressed to:

For Institution:

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Via Francesco Sforza 28
20122 Milano
Italy
Atten: Direzione Scientifico

For TargED:

TargED Biopharmaceuticals BV.
Princetonlaan 6
3584 CB, Utrecht
The Netherlands
Attn: C.E.O.

9.13. This Agreement shall be governed by and construed according to the laws of The Netherlands. Any action(s) that may arise out of this Agreement shall be brought before the competent court in The Hague (The Netherlands) for resolution.

9.14. Any controversy, claim or dispute that may arise out of this Agreement shall first be solved amicably. If an amicable settlement is not possible, any controversy, claim or dispute that may arise shall be submitted exclusively to the Court of the Institution's registered office.

9.15. The undersigned represent that they are authorized to sign this Agreement on behalf of the Parties hereto.

IN WITNESS WHEREOF, the Parties have executed this Agreement in duplicate as of the last date hereinafter written:

For and on behalf of TargED	For and on behalf of Institution
Signed by Kristof Vercruysse kristof Vercruysse Name: Kristof Vercruysse Function: Chief Executive Officer 931FFAFFEA7E4196A497ECC422873F53 Date: 6/11/2026	I approve this document 6/11/2026 | 4:32:05 AM PST Name: Fabio Blandini Function: Chief Scientific Officer Date:…….

Schedule A: description of services and payments

The research services will be performed in the context of the following trial:

Trial Protocol Number: TG1-CL-301

Protocol Full Title: An Adaptive Dose Escalation and Expansion Basket Trial to Explore the Safety, Pharmacology, and Clinical Activity of TGD001 in Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP) and Other Thrombotic Microangiopathies

Timelines

The abovementioned trial was initiated in the first investigational site in June 2026. Enrollment is expected to last until Q1 2028 with Last Patient Last Visit in Q2 2028.

Activities for the Institution will be initiated as soon as possible after the Effective Date and will last until 4 months after receipt of the last MRI image or last plasma sample, whatever occurs last.

Description of the Services - responsibility list

Activity- MRI	TargED	Institution
Contract and setup image transfer and de-identification portal	X	
Provide MRI feasibility checklist		X
Collect MRI feasibility checklist from participating sites	X	
Write image acquisition guideline		X
Ensure validation and qualification of software including documentation available for sponsor review	X	X
Ensure only authorized readers have access to MRI image		X
Review and approve image acquisition guideline	X	
Assess dummy image		X
Assess MRI images from study participants		X
Report data		X
Long term storage of MRI images	X	

Activity- VWF Multimer analysis	TargED	Institution
Provide participant frozen plasma samples	X	
Analyze VWF multimer in participant samples		X
Report data		X
Written report including data summary, materials & methods and conclusion		X
Shipment of remaining samples to central storage (to be defined by TargED)		X

Description of provided Materials

TargED will provide the following materials to the Institution for the Institution to be able to perform the Services:

- Clinical Trial Protocol
- Contact details investigational sites

- Login credentials to the electronic image transfer platform
- Anonymized MRI image data sets, transferred by electronic platform, from participants in the TG1-CL-301 trial. For each participant two timepoints are expected, a baseline and a follow-up scan.
- Platelet poor plasma for VWF Multimer analysis from participants in the TG1-CL-301 trial. For the initial 5 iTTP participants 6 timepoints from each participant are expected, sampled between baseline and +72 hrs after TGD001 administration. At each timepoint 2 aliquots, 0,5ml per aliquot are provided. After the samples from the initial 5 participants have been analysed by the Institution, TargED will determine the number of timepoints to be assessed for the remaining participants. In case a participant receives an optional repeat dose of TGD001, 3 additional timepoints will be provided, sampled between the repeat baseline and +24hrs after TGD001 repeat administration.
- Images and plasma samples will be identified through a participant number in the format XXX-YYY-ZZZ, where XXX is the 3-letter country code, YYY is the investigational center number and ZZZ is the participant number.

Deliverables

Institution will provide the following deliverables to TargED:

Deliverable - Imaging	**Timeline**
Image acquisition guideline	1 month after effective date
Dummy image assessment	Within 2 weeks after receipt of image
Participant image assessment	Quality check within 7 working days after receipt, assessment within 1 month after receipt of image
Report final data	8 weeks after Last Participant Last Visit
Support with analysis and description of data for article/narrative/Clinical Study Report	Deadline to be indicated by TargED

Deliverable - VWF Multimer analysis	**Timeline**
Provide participant frozen plasma samples	First batch within 4 weeks after completion of +72hr timepoint of the fifth participant Timeline for the shipment to be decided for remaining participants
Analyze VWF multimer in participant samples	Within 6 weeks after receipt of samples
Report data in excel format	Within 2 weeks after batch analysis
Written report including materials & methods, data summary and conclusion	4 weeks after last data report
Shipment of remaining samples on dry ice to central storage (location to be defined by TargED)	6 weeks after finalization of the written report

Other terms

Clinical and diagnostic responsibility remains entirely with the local/investigational site that acquired the MRI image. The central reviewers role is strictly limited to trial endpoint assessment and protocol-specific data reporting for research purposes, without clinical patient management liabilities.

The individual investigational sites will be trained on the use of the electronic transfer platform by TargED representatives. Central reviewers are not responsible for providing such training.

The individual investigational sites will be trained on the image acquisition specifications by means of the image acquisition guideline. TargED will provide all sites with an electronic or printed version of this guideline. Central reviewers are responsible for assessing the quality of the received images and for providing feedback to the sites for improvement of acquisition, if applicable.

Budget

Activity- MRI	**Unit**	**Unit fee (EUR)**	**Expected units**	**Total (EUR)**
Setup phase including contracting, kick-off meeting, image transfer training, documentation development and oversight by senior investigator during the project	Per Trial	10.000	1	10.000
Assess dummy MRI	Per Site	50	25	1.250
Assess MRI image (fee for image deemed sub-optimal or non-evaluable)	Per Timepoint	50	21 (15% of images expected to be sub-optimal)	1.050
Assess MRI image and report in excel (fee for evaluable image)	Per Timepoint	100	140 (2 timepoints per participant, 70 participants)	14.000
Data transfer of Institution to TargED	Per Transfer	250	6 (end of part A, end of part B, 4 ad-hoc transfers)	1.500
Write article/narrative/CSR	Per Trial	2.500	1	2.500
Closure of the services	Per Trial	1.000	1	1.000
Total				**31.300**

Activity- VWF multimer	**Unit**	**Unit fee (EUR)**	**Expected units**	**Total (EUR)**
Setup phase including contracting, kick-off meeting, documentation development and oversight by senior investigator during the project	Per trial	10.000	1	10.000
Assess VWF multimers	Timepoint	250	105 (6 timepoints per participant for initial 5 iTTP participants, 3 expected timepoints per participant for next 25 iTTP participants)	26.250
Assess VWF multimers	Timepoint	250	25 (3 timepoints for 25 participants – per optional repeat dose)	6.250
Data transfer of Institution to TargED	Transfer	250	4 (after 5 initial participants, end of trial, 2 ad-hoc transfers)	1.000
Write written report	Per trial	5.000	1	5.000

Closure of the services, including shipment of remaining samples	Per trial	1.000	1	1.000
Total				**49.500**

Payment schedule

The following terms apply to this budget:

- Fees will be invoiced to TargED when units described above are completed. The units provided in Attachment A are estimates only and the actual units incurred will be invoiced.
- Invoices will be sent by the Institution to TargED quarterly.
- No other expenses are expected to be made (translation fees, travel, fax, phones and printing fees).
- Courier costs for sample shipment are expected to be invoiced to TargED as pass-through costs.
- Unit fee for VWF multimer assessment is including reagents and any other materials.
- Unit fee for assessing the MRI image: fee of 50 EUR may be invoiced per timepoint if the received images are deemed to be non-evaluable or of sub-optimal quality. This fee includes communicating the reason for being non-evaluable or sub-optimal to the investigational site. In case an evaluable image is received for the timepoint, replacing the non-evaluable image, the fee for an evaluable image may be invoiced on top of the fee for the non-evaluable image.
- Unit fee for assessing the MRI image: fee of 100 EUR may be invoiced per timepoint for an evaluable image, including the reporting of results in excel.
- Inflation costs are expected to be considered in the above agreed budget. If the services are extended beyond the initially agreed timelines, a yearly inflation rate of 3% can be invoiced from the initially agreed end date onwards.

Certificate Of Completion

Envelope Id: 4E2DB2DE-D046-8D8C-812D-460281C7873F
Status: Completed
Subject: Complete with Docusign: TG1-CL-301 TargED - Fondazione IRCCS Milan Research Services Agreement_...
Source Envelope:
Document Pages: 18
Signatures: 1
Certificate Pages: 5
Initials: 0
AutoNav: Enabled
EnvelopeId Stamping: Disabled
Time Zone: (UTC-08:00) Pacific Time (US & Canada)

Envelope Originator:
Barbara van den Aarsen
Croeselaan 361
Utrecht, Utrecht 3521 BW
barbara.van.den.aarsen@Targedbio.com
IP Address: 86.86.173.7

Record Tracking

Status: Original
11/6/2026 1:29:18 AM
Holder: Barbara van den Aarsen
barbara.van.den.aarsen@Targedbio.com
Location: DocuSign

Status: Original
11/6/2026 4:32:29 AM
Holder: TargED Biopharmaceuticals
info@targedbio.com
Location: DocuSign

Signer Events	Signature	Timestamp
Kristof Vercruysse kristof.vercruysse@targedbio.com CEO Targed Biopharmaceuticals Security Level: Email, Account Authentication (Required), Logged in	Signed by Kristof Vercruysse Kristof Vercruysse I approve this document 6/11/2026 | 4:32:05 AM PST 931FFAFFEA7E4196A497ECC422873F53 Signature Adoption: Pre-selected Style Signature ID: 931FFAFF-EA7E-4196-A497-ECC422873F53 Using IP Address: 37.139.127.131 Signed using mobile With Signing Authentication via Docusign password With Signing Reasons (on each tab): I approve this document	Sent: 11/6/2026 1:30:22 AM Viewed: 11/6/2026 4:31:50 AM Signed: 11/6/2026 4:32:25 AM

Electronic Record and Signature Disclosure:
Accepted: 11/1/2023 5:54:52 AM
ID: 89cebab9-8cbd-4fc2-8413-d62bc6270110

In Person Signer Events	Signature	Timestamp

Editor Delivery Events	Status	Timestamp

Agent Delivery Events	Status	Timestamp

Intermediary Delivery Events	Status	Timestamp

Certified Delivery Events	Status	Timestamp

Carbon Copy Events	Status	Timestamp
Barbara van den Aarsen barbara.van.den.aarsen@Targedbio.com Security Level: Email, Account Authentication (Required)	COPIED	Sent: 11/6/2026 4:32:29 AM Viewed: 11/6/2026 4:32:29 AM Signed: 11/6/2026 4:32:29 AM

Electronic Record and Signature Disclosure:
Accepted: 1/23/2026 4:22:50 AM
ID: 5c9cb599-ae4b-45ec-b531-e499a15aa5e0

Witness Events	Signature	Timestamp

Notary Events	Signature	Timestamp

Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	11/6/2026 1:30:22 AM
Certified Delivered	Security Checked	11/6/2026 4:31:50 AM
Signing Complete	Security Checked	11/6/2026 4:32:25 AM
Completed	Security Checked	11/6/2026 4:32:25 AM

Payment Events	Status	Timestamps

Electronic Record and Signature Disclosure

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Marc van Moorsel (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a $0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Marc van Moorsel:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:
To contact us by email send messages to: info@targedbio.com

To advise Marc van Moorsel of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at info@targedbio.com and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Marc van Moorsel

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to info@targedbio.com and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Marc van Moorsel

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;

ii. send us an email to info@targedbio.com and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: https://support.docusign.com/guides/signer-guide-signing-system-requirements.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

By selecting the check-box next to 'I agree to use electronic records and signatures', you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Marc van Moorsel as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Marc van Moorsel during the course of your relationship with Marc van Moorsel.